Fluticasone propionate

Generic Name: Fluticasone propionate

Brand Names: Advair, Airduo, Airduo Respiclick, Aller-flo, Armonair, Beser, Cutivate, Dymista, Flonase, Flovent, Fluticare, Ticanase, Wixela, Xhance

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₁F_₃O_₅S

CAS Number: 80474-14-2

Unique Ingredient Identifier: O2GMZ0LF5W

Background: Fluticasone propionate is a synthetic glucocorticoid. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications. Fluticasone propionate was first approved in 1990.

Indication: Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.

Associated Conditions: Allergic Rhinitis (AR), Allergy to Animal Dander, Allergy to Mold, Allergy to Tree Pollen, Asthma, Bacterial Sinusitis, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Chronic Sinusitis, Dermatitis, Emphysema, Eosinophilic Esophagitis, House Dust Mite Allergy, House dust allergy, Itching of the nose, Nasal Congestion, Non-Allergic Rhinitis, Rhinitis, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Moderate, severe Perennial Allergic Rhinitis (PAR), Moderate, severe Seasonal Allergic Rhinitis

Associated Therapies: -

Clinical Trials

Management of Recurrent Croup

Phase 3

Terminated

Conditions: Croup

Interventions: Drug: Prednisolone IF needed
Drug: Fluticasone

First Posted Date: 2012-12-12

Last Posted Date: 2017-11-13

Lead Sponsor: University of Michigan

Target Recruit Count: 10

Registration Number: NCT01748162

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Effects of QVAR in Smokers With Asthma

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Beclomethasone (QVAR)
Drug: Beclomethasone (Clenil)
Drug: Fluticasone

First Posted Date: 2012-12-04

Last Posted Date: 2016-08-26

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 40

Registration Number: NCT01741285

Locations: 🇳🇱
University Medical Center Groningen, Groningen, Netherlands

Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone

Phase 3

Withdrawn

Conditions: Eosinophilic Esophagitis
Dysphagia

Interventions: Drug: Fluticasone
Drug: Montelukast

First Posted Date: 2012-10-08

Last Posted Date: 2019-08-28

Lead Sponsor: Medical College of Wisconsin

Registration Number: NCT01702701

Locations: 🇺🇸
GI Associates, Milwaukee, Wisconsin, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device

Phase 3

Completed

Conditions: Bilateral Nasal Polyposis

Interventions: Drug: Fluticasone propionate

First Posted Date: 2012-06-21

Last Posted Date: 2018-12-05

Lead Sponsor: Optinose US Inc.

Target Recruit Count: 323

Registration Number: NCT01624662

Locations: 🇺🇸
Allergy and Asthma Research Group, Eugene, Oregon, United States
🇺🇸
Institute for Asthma and Allergy, Wheaton, Maryland, United States
🇺🇸
University of Vermont, Burlington, Vermont, United States

and more 7 locations

New Serological Markers for Eosinophilic Esophagitis

Conditions: Eosinophilic Esophagitis

Interventions: Drug: Fluticasone

First Posted Date: 2012-06-20

Last Posted Date: 2012-06-20

Lead Sponsor: Technical University of Munich

Target Recruit Count: 20

Registration Number: NCT01624129

Locations: 🇩🇪
II. Medical Department, Technical University Munich, Munich, Bavaria, Germany

Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps

Phase 3

Completed

Conditions: Chronic Sinusitis With or Without Nasal Polyps

Interventions: Drug: Fluticasone Propionate

First Posted Date: 2012-06-19

Last Posted Date: 2016-08-29

Lead Sponsor: Optinose US Inc.

Target Recruit Count: 705

Registration Number: NCT01623323

Locations: 🇺🇸
InterMountain Ear Nose and Throat, Salt Lake City, Utah, United States
🇺🇸
Institute for Asthma and Allergy, Wheaton, Maryland, United States
🇺🇸
Texas Quest Medical Research, San Antonio, Texas, United States

and more 14 locations

Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety

Phase 3

Completed

Conditions: Bilateral Nasal Polyposis

Interventions: Drug: Fluticasone Propionate

First Posted Date: 2012-06-19

Last Posted Date: 2018-12-26

Lead Sponsor: Optinose US Inc.

Target Recruit Count: 323

Registration Number: NCT01622569

Locations: 🇺🇸
California Allergy & Asthma Medical Group, Inc., Los Angeles, California, United States
🇺🇸
Clinical Research Group of Montana, PLLC, Bozeman, Montana, United States
🇺🇸
NU Feinberg School of Medicine Depart. of Otolaryngology-Head & Neck Surgery, Chicago, Illinois, United States

and more 30 locations

12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device

Phase 3

Completed

Conditions: Nasal Polyps

Interventions: Drug: Fluticasone Propionate

First Posted Date: 2012-06-19

Last Posted Date: 2018-01-24

Lead Sponsor: Optinose US Inc.

Target Recruit Count: 223

Registration Number: NCT01623310

Locations: 🇺🇸
Exemplar Research, Fairmont, West Virginia, United States
🇺🇸
Achieve Clinical Research, Birmingham, Alabama, United States
🇺🇸
Sneeze Wheeze and Itch Associates, Normal, Illinois, United States

and more 13 locations